Hypereosinophilic syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →

At a Glance

Live from database

1FDA treatments

9Recruiting trials

Regulatory Watchboard

10 events

Apr 2026Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications

Seoul National University Hospital — PHASE4

TrialNOT YET RECRUITING

Mar 2026Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

AstraZeneca — PHASE3

TrialNOT YET RECRUITING

Jan 2026A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Kymera Therapeutics, Inc. — PHASE2

TrialRECRUITING

Dec 2025A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

AstraZeneca

TrialRECRUITING

Dec 2025A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma

Advagene Biopharma Co. Ltd. — PHASE2

TrialNOT YET RECRUITING

Oct 2025REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)

Western University, Canada — NA

TrialNOT YET RECRUITING

Jun 2025The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome

Fondazione IRCCS Policlinico San Matteo di Pavia — NA

TrialRECRUITING

Apr 2025Eosinophil Subpopulations in Eosinophilic-associated Diseases

University of Florence

TrialNOT YET RECRUITING

Mar 2025Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

AstraZeneca — PHASE3

TrialRECRUITING

Feb 2025Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

National Institute of Allergy and Infectious Diseases (NIAID) — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Hypereosinophilic syndrome.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

NUCALA

(mepolizumab)Orphan drugstandard

GlaxoSmithKline LLC

Interleukin-5 Antagonist [EPC]

12.1 Mechanism of Action Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, re...

View full treatment details on disease page →

Clinical Trial Landscape

9 active trials

2Phase 3

3Phase 2

1N/A

3Unknown

9Total recruiting

Search clinical trials for Hypereosinophilic syndrome →

Recent News & Research

No recent news articles indexed yet for Hypereosinophilic syndrome.
Search PubMed for Hypereosinophilic syndrome →

Browse all Hypereosinophilic syndrome news →

Specialist Network

Top 6 by expertise

Amy D Klion, M.D.

National Institute of Allergy and Infectious Diseases (NIAID)

📍 BETHESDA, MD

Score 68 trials

Gunnar Bentsen, MD

Oslo University Hospital

Score 42 trials1 pub

Harry Hemingway, FRCP

University College, London

Score 23 trials

Michele BACCARANI

Azienda Ospedaliera Universitaria -Policlincio S. Orsola-Malpighi

Score 04 trials

Lionel Prin

University Hospital, Lille

Guillaume LEFEVRE

University Hospital, Lille

Score 03 trials

View all Hypereosinophilic syndrome specialists →

Quick Actions

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants

Latest News

Research, approvals & updates

Browse All Diseases

11,000+ rare disease profiles